You reviewed ....
for this content
out of 5
Event : Heart Failure 2019
Topic : Other
Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.
Heart Failure 2019
Sacubitril valsartan, a multicentric experience
Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy
Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy
Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy
Benefits of early administration of ivabradine in stabilized patients hospitalized due to worsening heart failure: insights from the Optimize Heart Failure Care Program
Series of patients treated with sacubitril-valsartan in a cardiology day clinic: efficacy and safety after 6 months of follow-up
Effects of empagliflozin on exercise capacity and LV diastolic function in HFpEF and type-2 diabetes mellitus: rationale and design of prospective intervention study
Titration process and predictors of achieving target dose of sacubitril/valsartan in patients with chronic heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.
Nitrates in female patients with diabetes mellitus and without diabetes mellitus in reduced ejection fraction heart failure
Microcirculation changes in combination therapy in patients with heart failure with preserved ejection fraction.
Effects of perindopril on levels of endothelial dysfunction biomarkers in chronic heart failure patients with mid-range ejection fraction after 12-month therapy
Sacubitril/valsartan in chronic symptomatic heart failure: a real world experience of delivery and outcomes.
Outpatient inotrope administration in advanced heart failure patients: a single centre experience.
Atrial fibrillation in Dutch chronic heart failure with reduced ejection fraction patients: the CHECK-HF registry
Reduced diuretic requirements in HFreF patients taking Entresto (ARNI)
Sacubitril/Valsartan in real world heart failure proctice in Asia
Reduction of loop diuretic requirements in HFrEF patients treated with Sacubitril/Valsartan
Recovery of left ventricular dysfunction after Sacubitril/valsartan: predictors and managements
Safety, tolerability and discontinuation causes of sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.
Outcomes of adherence to guideline in heart failure management: the role of heart failure specialist
Valsartan improves ventriculo-vascular coupling index dose-dependently in heart failure with reduced left ventricular ejection fraction
Factors that influence Heart Failure treatment titration in a Heart Failure Unit
Potentially inappropriate medication use in elderly patients with heart failure: beers criteria-based review
Baseline characteristics, treatment dosage, and clinical outcomes of post-acute HFrEF patients initiated with Sacubitril/Valsartan
Central sleep apnea in patients with chronic heart failure and its treatment with acetazolamide
The investigation of efficacy and safety about the clinical pathway for congestive heart failure specified immediate use of tolvaptan after admission in super-elderly patients.
Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension and dose titration
Sacubitril-valsartan treatment furtherly improves response to intermittent parenteral levosimendan in ambulatory patients with advanced heart failure with reduced ejection fraction
Significant underutilization of angiotensin receptor neprolysin inhibitor (ARNI) and other evidence-based heart failure (HF) therapies in an outpatient clinic setting
Effectiveness of early administration of Tolvaptan for cardiac prognosis in acute decompensated heart failure
Sacubitril/Valsartan: for all patients?
Effects of statins on major adverse cardiovascular events in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
An evaluation of consultant and registrar prescribing in the outpatient setting
Frailty quick test, effective for risk stratification of inadequate treatment of heart failure
Effect of sacubitril/valsartan in real-world patients in South London
Impact of beta blockers therapy on right ventricular function in heart failure patients with reduced ejection fraction a prospective evaluation
Clinical experience with ambulatory perfusion of levosimendan in an advanced heart failure unit
Treatment of patients with chronic heart failure: does management in heart failure clinic improve adherence to guidelines for the treatment of heart failure?
Intermittent infusions of levosimendan in advanced heart failure: last but not least; a single-centre clinical experience on the efficacy of repeated levosimendan infusions.
Study of effect of therapy of chronic obstructive pulmonary disease on coexistent chronic heart failure
Polypharmacy in patients with chronic heart failure
Changes in hemodynamic profile in patients with severe systolic dysfunction treated with sacubitril-valsartan
Sacubitril/valsartan inverse remodeling - a prospective echocardiographic study
Initial clinical experience with the first drug (sacubitril/valsartan) in a new class -arni- in afro-caribbean patients with heart failure and reduced ejection fraction
Empagliflozin in heart failure: beyond clinical endpoints
ARNI use in clinical practice: PARADIGM-HF trial results applied to the real world
MYK-491, a novel cardiac myosin activator, increases cardiac contractility in healthy volunteers
Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis
A low dose Pimobendan was observed to prolong the period until re-hospitalization for Japanese patients with advanced heart failure, especially in the vulnerable post-discharge period.
microRNA-21 as a prognostic biomarker of sacubitril/valsartan treatment response in heart failure with reduced ejection fraction
Metabolism and pharmacokinetic drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator
Are we optimizing medical therapy during a heart failure hospitalisation ?
Sacubitril/Valsartan in clinical practice, how does it work?
Get your access to resources
Our mission: To reduce the burden of cardiovascular disease